×

Neville Registrars is delighted to welcome Volvere plc as the newest addition to its list of client companies.

Volvere is an industrial holding company that invests in or acquires companies which require growth capital.

Further information can be found on the Company's website: https://www.volvere.co.uk/

Close

×

Neville Registrars is delighted to welcome NMT Group Limited as the newest addition to its list of client companies.

NMT is a medical devices company that developed a safety syringe to prevent needlestick injury. 

Further information can be found as follows: https://www.volvere.co.uk/current-portfolio/nmt-group.aspx

Close

×

Neville Registrars is delighted to welcome Craven House Capital Plc as the newest addition to its list of client companies.

Craven House Capital is a merchant bank in the 18th and 19th Century context of the term.

Further information can be found on the Company's website: http://www.cravenhousecapital.com/

 

Close

×

Neville Registrars is delighted to welcome Eco Equity Limited as the newest addition to its list of client companies.

Eco Equity is a pharmaceutical supplier of medicinal cannabis.

Further information can be found on the Company's website: https://www.eco-equity.com/

Close

×

RNS Number : 2915I

Deepverge PLC

11 December 2020

 

11 December 2020

 

DeepVerge PLC

 

("DeepVerge" or "the Company")

 

 

New Labskin service 'soft  launched' in August already nets £400,000 in completed orders in Q4

 

Service has attracted new household name clients

 

 

DeepVerge (LSE:DVRG.L), the environmental and life science AI company, is pleased to announce a new R&D service, launched in August 2020, has already generated £400,000 in completed sales in Q4 with agreements with 10 new clients that had previously not used Labskin services. These agreements include framework Master Services Agreements with 2 of the world's largest suppliers of consumer products related to skincare.

 

The new service, designed to quickly validate the impact of ingredients such as probiotics and prebiotics on the skin microbiome, clones the human skin microbiome using six microbial strains and delivers real world environment results that mirror the impact of treatments and therapeutics on real human skin.

 

The new R&D service adds to the existing client offering. It increases revenue per client and delivers higher value test services on ingredients used in an expansive range of products – from anti-viral, to shampoos to babies' nappies.  The new service replicates skin conditions of the scalp, face, mouth and abdomen. It also utilises AI which has significantly improved the speed and accuracy of testing ingredients on virtual skin models.

 

 

Gerard Brandon, CEO of DeepVerge, Commented:

 

"When we designed this new service we built on three key platforms : Labskin's ability to grow human skin, its expertise in replicating the skin's microbial environment from different parts of the body and its increasing use of AI and data which helps with speed, accuracy and insights. While we will fully launch the product at conferences across all regions in 2021, it has already resulted in significant interest and orders from existing and new clients as well as from new clients in new sectors/markets.

 

The Labskin division has become a recognised global leader in cloning and testing real-world human skin microbiome in a laboratory with a rapidly expanding order book from a growing blue chip client base. Since September 2019, the team has increased revenue per client exponentially by offering multiple value-added solutions beyond its core laboratory testing services which lower client development costs of product information validation enabling new products get to market faster."

 

For further information please contact:

DeepVerge plc	Gerard Brandon, CEO	+44 (0) 7340 055 648
SPARK Advisory Partners Limited (Nominated Adviser)	Neil Baldwin/Andrew Emmott	+44 (0) 113 370 8974
Turner Pope Investments (TPI) Limited (Broker)	Andy Thacker/Zoe Alexander	+44 (0) 20 3657 0050

 

About DeepVerge plc (www.deepverge.com)

DeepVerge is a scientific research and AI-as-a-Service company focused on production and analysis of bacteria, virus and toxins utilising artificial intelligent data analytics in regulatory technology, from scientifically proving the impact of skincare product claims on skin microbiome for top 20 global cosmetic company clients to remotely detecting water contamination in real-time.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

MSCURVNRRRUUAAA

Close

×

Volvere is an industrial holding company that invests in or acquires companies which require growth capital. 

Further information can be found on the Company’s website: https://www.volvere.co.uk/

Close

×

RNS Number : 9798H

Osirium Technologies PLC

09 December 2020

 

9 December 2020

REACH

 

 

Osirium Technologies plc

("Osirium" or "Group")

 

Contract win with additional major UK Ambulance Service

 

Osirium Technologies plc (AIM: OSI.L), a leading vendor of cloud-based cybersecurity software, is pleased to announce a contract win with an additional major regional UK Ambulance Service.

 

The new contract represents a further instance of Osirium displacing an incumbent PAM provider and being selected in preference to other PAM vendors. The initial order is for the Osirium PAM platform including the Privileged Access Management, Privileged Task Management and Privileged Session Management modules for 375 devices over a 36-month term. 24/7 support, professional services and training are included in the contract.

The order continues Osirium's success in 2020 in securing business from the UK Ambulance Service sector in conjunction with ITHealth, an approved reseller partner specialising in cybersecurity for healthcare service providers. Key factors in the selection are Osirium's local presence and 24/7 support capabilities, flexibility of licensing, breadth of PAM functionality, and ease of deployment and use.

The principal initial d river for the client in this contract is demonstrating compliance with the NHS Data Protection Security Toolkit directive, to provide assurance of good data security practices and correct handling of personal information. The Osirium PAM platform will be used to carry out a number of functions across a mixed Windows and networking environment, including backups, controlling access, managing credentials, and providing a comprehensive, end to end audit trail. The client also sees real value in applying Osirium's task and process automation capabilities. This allows them to securely delegate activities requiring privileges to staff outside the immediate project team, and, thus, reduce workload strain on specialist IT resources.

Subsequent phases will also include secure management of 3rd party access to the infrastructure, as well as additional controls for internal access.

Following the announcement of a contract win with a major UK communications and mobile services provider on 2 December 2020, this new contract is a further endorsement of Osirium's strategy and strong commercial momentum.

 

David Guyatt, Chief Executive Officer, commented : "I am delighted that Osirium has been able to secure another win in the NHS and Emergency Services sector and, yet again, displace an incumbent PAM supplier. This contract endorses multiple aspects of our strategy: our focus on simplicity and ease of deployment that other vendors fail to match; our partnership with quality specialist integrators; our commercial flexibiltity and agility in securing this order within a three month sales cycle; and our commitment to providing ourstanding support to our customers." 

 

 

–  Ends –

For further information:

Osirium Technologies plc	Tel: +44 (0) 118 324 2444
David Guyatt, Chief Executive Officer Rupert Hutton, Chief Financial Officer www.osirium.com
Stifel Nicolaus Europe Limited (Nominated Adviser and Broker)	Tel: +44 (0) 20 7710 7600
Fred Walsh / Richard Short
Alma (Financial PR) David Ison / Josh Royston / Kieran Breheny	Tel: +44 (0) 203 405 0205

 

Notes to Editors:

Osirium Technologies plc (AIM: OSI) operates in one of the fastest growing parts of the cybersecurity market and is a leading vendor of Privileged Access Security solutions. Osirium's cloud-based products protect critical IT assets, infrastructure and devices by preventing targeted cyber-attacks from directly accessing Privileged Accounts, removing unnecessary access and powers of Privileged Account users, deterring legitimate Privileged Account users from abusing their roles and containing the effects of a breach if one does happen.

Osirium has defined and delivered what the Directors view as the next generation Privileged Access Management solution. Osirium's award-winning Privileged Task Management module further strengthens Privileged Account Security by minimising the cyber-attack surface and delivering an impressive return on investment benefits for customers. Building on Osirium's Privileged Task Management module, in May 2019 Osirium launched Privileged Process Automation, providing a highly-flexible platform for automating essential IT processes to set a new benchmark in IT Process Automation. This was followed by the launch of Privileged Endpoint Manager in December 2019, bringing the total portfolio to three complementary solutions.

Founded in 2008 and with its headquarters in Reading, UK, the Group was admitted to AIM in April 2016. For further information please visit www.osirium.com.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NRAEAKAPESDEFFA

Close

×

RNS Number : 9286H

e-Therapeutics plc

08 December 2020

 

e-therapeutics plc

("e-therapeutics" or the "Company")

 

COVID-19 Project Update

 

 

 

Oxford, UK, 8 December 2020 – e-therapeutics plc (AIM: ETX) announces the results of experimental testing on the compounds for the treatment of COVID-19 identified using its proprietary Network-driven Drug Discovery (NDD) platform.

In March 2020, the Company announced its intention to deploy its network biology platform to identify clinical stage compounds that either singly or in combination could be repurposed rapidly to treat COVID-19. We chose to approach this by focussing on therapeutic strategies that target host systems, thereby minimising the risk of resistance and potentially being effective for the treatment of other viral infections.

From our previous work using network models of SIRS (Systemic inflammatory response syndrome) seen in indications such as sepsis, we had identified a class of small molecule compounds, a mechanism and target that was able to silence the 'cytokine storm' generated in human blood cells by a range of inflammatory triggers. In March 2020, we undertook an in silico analysis of data sets from human cells infected with SARS-CoV-2 and generated network models of the cellular machinery that the virus had 'hijacked'. Analysis of both our SIRS work and the SARS-CoV-2 networks revealed a key common process which was simultaneously important to the virus and the hyperinflammatory response. Our platform predicted that inhibition of the same target, GRP94, that was effective in suppressing hyperinflammation would also be effective in disrupting the virus's ability to replicate.

In May 2020, small molecule compounds predicted by our platform were tested in validated SARS-CoV-2 in vitro assays at WuXi AppTech. These compounds showed potent anti-inflammatory and anti-viral activity. We report here that in vitro assays have confirmed our in silico predictions and we have identified a clear mechanism, target and clinical stage compounds. These compounds are active against GRP94 and have anti-inflammatory and anti-viral activity against Sars-CoV-2. This activity generalises to other alpha and beta coronaviruses and is expected to be generically applicable, raising the prospect of utility against both existing coronaviruses that cause serious disease such as SARS and MERS and against new emergent strains of coronavirus.

The clinical stage compounds identified have been developed in humans for alternative indications and have an established safety profile in man. These, and other selective compounds sharing this target, could be rapidly deployed into clinical trials to treat patients with serious Covid-19 disease. Given our mechanistic insights, it would also be feasible to develop novel, highly selective drugs against GRP94. We continue to work on repurposable combinations using our platform and have compound combinations currently in testing. We anticipate data that will enhance our understanding further in Q1 2021.

Chairman & CEO Ali Mortazavi said:

" e-therapeutics' platform has the ability to start with any biological process of relevance to disease and to identify compounds and targets that can modulate that process in a therapeutic setting. This data set is a strong validation of our platform and the network biology approach to drug discovery. e-therapeutics' computational biology platform is capable of discovering new chemical matter, novel drug targets and uncovering new mechanisms. Here, we have deployed that capability to investigate known compounds in a novel context. We have uncovered new mechanisms that mitigate infection-induced hyperinflammation as well discovering a potent anti-viral strategy. Our findings have highlighted Bardoxolone Methyl which is already the subject of an investigator led COVID-19 trial (NCT04494646).

The surprise finding of this compound's anti-viral activity alongside its well observed anti-inflammatory properties has led us to file a patent (GB2017631.9) which describes the use of Bardoxolone and related compounds to treat Covid-19 and other viral diseases. Previous knowledge of similar compounds has focused on the activation of the NRF2 pathway. Here, we show that both the anti-viral and anti-inflammatory properties we have observed depend on GRP94. We demonstrate that other selective GRP94 inhibitors may also be active anti-virals against a range of coronaviruses. Should Bardoxolone Methyl be progressed from its Phase 2 safety evaluation in NCT04494646 into Phase 3, we would be happy to share our anti-viral analysis with the sponsor.

To date, no compounds with this type of potent dual activity have been reported and clinical approaches have focused on combination drug therapies using anti-inflammatory compounds such as dexamethasone combined with anti-virals such as Remdesivir. Irrespective of our findings for Bardoxolone, we believe that our project will open deeper interest in selective GRP94 inhibitors and GRP94 as a possible target for future development of therapeutics not only for COVID induced hyper-inflammation/infection but potentially other viral infections. A presentation can be found on our website at : https://www.etherapeutics.co.uk/wp-content/uploads/2020/12/COVID-Project-Update-05122020.pdf The company intends to publish this work in a highly regarded scientific journal in the coming months."

-Ends-

 

 

For further information, please contact:

 

e-therapeutics plc Ali Mortazavi, CEO	Tel: +44 (0)1993 883 125 www.etherapeutics.co.uk
Numis Securities Limited Freddie Barnfield/Duncan Monteith (Nominated Adviser)  James Black (Corporate Broking)	Tel: +44 (0) 207 260 1000  www.numis.com

 

About e-therapeutics plc

 

e-therapeutics plc is an Oxford, UK-based company with a powerful computer-based approach to drug discovery, founded on its industry-leading expertise in network biology to fully capture disease complexity. The Company combines network science, machine learning, artificial intelligence, statistics and access to big data with expertise in drug discovery and development to transform the search for new medicines and intervention strategies.

 

e-therapeutics has developed an in silico laboratory that enables the rapid screening of millions of compounds and the identification of small sub-sets that are enriched for highly active hits. Its proprietary platform also has novel applications in functional genomics, being able to analyse complex genetic datasets, provide a deep understanding of pathological mechanisms and distil actionable insights for the discovery of novel drugs, biomarkers and diagnostics.

 

e-therapeutics has deployed and validated its disease-agnostic drug discovery platform both in house and with partners, including Novo Nordisk, Galapagos NV and a US-based, top 5 pharmaceutical company.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

UPDUWRARRNUURAA

Close

×

RNS Number : 3517H

N4 Pharma PLC

03 December 2020

 

3 December 2020

N4 Pharma plc

("N4 Pharma" or the "Company")

 

Formulation Work Update

 

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to provide the following update on its ongoing research collaboration agreement with Nanomerics Limited ("Nanomerics").

 

As announced on 11 February 2020, the Company initiated the first phase of research to test the stability of different formulations of Nuvec® loaded with a well characterised plasmid DNA. The Company is pleased to report that, in addition to not degrading the plasmid DNA, which it announced on 5 November 2020, Nuvec® formulations that had been freeze dried and then stored for 14 days either at room temperature or at four degrees Celsius, showed no significant drop in in vitro transfection capability following reconstitution compared to fresh formulations.

 

In parallel to continued work on analysing stability duration, different formulations will now be chosen to move forward into phase two of the work programme testing the efficacy of the dried and reconstituted plasmid DNA in an in vivo antibody generation model .

 

 

Nigel Theobald, Chief Executive Officer of the Company, commented:

 

"Demonstrating that Nuvec® loaded with a plasmid DNA can be dried, stored at convenient temperatures and reconstituted without any drop in transfection is a significant step forward in our formulation development work.

 

"The recent success of Pfizer and Moderna with an mRNA Covid-19 vaccine shows the potential for nucleic acid vaccines. However, it also highlights that these vaccines have certain limitations, in that they often require extreme storage conditions.

 

"Although vaccine efficacy is predominantly determined by the selected nucleic acid antigen, having a stable, easy to store and easy to use vaccine is crucial in helping vaccine acceptance and uptake. A formulation stable at room temperature or even refrigerated can represent significant cost savings in vaccine transportation, storage and administration. We believe, to the extent that Nuvec® as a delivery platform can provide a solution in this area, it could be of significant interest to multiple vaccine developers.

 

"Work will continue in this area and will add to the breadth of proof of concept data we are building for the use of Nuvec® as a delivery system for vaccines and cancer treatments."

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014.

 

Enquiries:

 

N4 Pharma plc
Nigel Theobald, CEO	Via IFC Advisory
Luke Cairns, Executive Director
SP Angel Corporate Finance LLP	Tel: +44(0)20 3470 0470
Nominated Adviser and Joint Broker
Matthew Johnson/Caroline Rowe (Corporate Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
Turner Pope Investments (TPI) Limited	Tel: +44(0)20 3657 0050
Joint Broker
Andy Thacker
IFC Advisory Ltd Financial PR Graham Herring Zach Cohen	Tel: +44(0)20 3934 6630

 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre-clinical and clinical programs, N4 Pharma will seek to receive up-front payments, milestone payments and ultimately royalty payments once products reach the market.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

MSCBCBDDUBGDGGD

Close

×

RNS Number : 1788H

IDOX PLC

02 December 2020

 

2 December 2020

RNS Reach

 

Idox plc

('Idox' or the 'Group' or the 'Company')

 

Contract Win

Idox partnership to deliver election e-Counting solution to Scottish Government

ldox (AIM: IDOX), a leading supplier of specialist information management software and solutions,  today announces a contract with the Scottish Government and Scottish Local Authorities, to deliver the electronic counting of ballot papers for the scheduled Local Authority elections in 2022 and future Scottish elections.

Working in partnership with Fujitsu and Elite Training, the five-year contract, won under open tender, will see Idox provide e-Counting election support for the Scottish Government and Scottish Local Authorities for the third consecutive time, having been selected to provide software and print management services in the 2016 and 2017 Scottish Local Government elections.

David Meaden, Chief Executive Officer of Idox said:

"Our strategic partnership with Fujitsu and Elite Training provides a market-leading e-Counting solution that will help drive efficiency and improve the Scottish elections' process. The contract marks an important win for Idox, showcasing our full capabilities in electoral services whilst improving our revenue visibility for FY21 and beyond."

-Ends-

Enquiries :

Idox plc          +44 (0) 870 333 7101

Chris Stone, Non-Executive Chairman
David Meaden, Chief Executive
Rob Grubb, Chief Financial Officer


MHP Communications                             +44 (0) 203 128 8170
Reg Hoare / James Bavister / Amy O'Sullivan                                                                           [email protected]

About Idox plc

For more information see  www.idoxplc.com   @Idoxgroup

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NRATBBFTMTTMBRM

Close